Personalized Medicine: A Reality Within this Decade
Tóm tắt
Personalized medicine is defined as individualized treatment based on the individual’s genetic variants. Such treatment has the potential to enable pharmacogenetics, such as the prevention of 100,000 deaths per year in the USA because of adverse drug reactions or specify treatment in heart failure such at the beta 1 adrenergic receptor polymorphisms. It is claimed that coronary artery disease (CAD) is at least 50% because of genetic predisposition. Identification of the genes predisposing to CAD would greatly facilitate prevention, early treatment, and more specific therapies. The arrival of the multimillion single nucleotide polymorphism (SNP) array provides the high throughput genotyping required to perform genome-wide Association (GWA) studies. These studies require markers (SNPs) at intervals of 6,000 bp and sample size of several thousands. Platforms are available to genotype and process millions of genotypes per day. The GWA performed by the Ottawa Heart Genomic Study identified the first deoxyribonucleic acid region (9p21) predisposing to CAD after replication in six independent populations totaling 23,000. This was subsequently confirmed in several independent studies totally more than 45,000 individuals. The region confers a risk for CAD independent of known risk factors. 9p21 occurs in heterozygous form in 40 to 50% of Caucasians with increased risk of 15 to 20% and in homozygous form in 25% of Caucasians with increased risk of 40%. Identification of the genes predisposing to CAD is a prerequisite for personalized care of these patients. It is anticipated that most of the genes predisposing to CAD will be identified in the next 5 to 8 years. The 9p21, in addition to conferring increased risk, provides the bonus of being independent of known risk factors. Thus, 9p21 is likely to provide the impetus and nidus for a major research effort over the next few years. It has the potential to not only provide for early genetic screening but also as a target for novel therapy.
Tài liệu tham khảo
Couzin, J. (2005). Drug safety: Gaps in the safety net. Science, 307(5707), 196–198 (Jan 14).
Service, R. F. (2005). Pharmacogenomics: Going from genome to pill. Science, 308(5730), 1858–1860 (Jun 24).
Couzin, J. (2005). DNA tells story of heart drug failure. Science, 307(5712), 1191.
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Awezum, A., Lanas, F., et al. (2004). Effect of potentially modifiable risk factors associated with myocardial infarctioon in 52 countries (the INTERHEART study case-control study). Lancet, 364(9438), 937–952.
Wald, N. J., & Law, M. R. (2003). A strategy to reduce cardiovascular disease by more than 80%. British Medical Journal, 326, 1419–1423 (Jun 28).
Roberts, R., & Stewart, A. F. R. (2006). Personalized medicine: A future prerequisite for the prevention of coronary artery disease. American Heart Journal, 4, 4(3), 222–227.
Arnold, K. (2003). Setting goals for cancer mortality: Earlier initiatives offer lessons for the future. Journal of the National Cancer Institute, 95(20), 1500.
Vaidya, D., et al. (2007). Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up. American Journal of Cardiology, 100, 1410–1415.
World Health Organization (2007). Facing the facts: The impact of chronic disease is Canada. Geneva: World Health Organization.
Allen, G., Harvald, B., & Shields, J. P. (1967). Measures of twin concordance. Acta Genetica et Statistica Medica, 17, 475–481.
Chan, L., & Boerwinkle, E. (1994). Gene–environment interactions and gene therapy in atherosclerosis. Cardiology in Review, 2(3), 130–137.
Hunt, S. C., Gwinn, M., & Adams, T. D. (2003). Family history assessment: Strategies for prevention of cardiovascular disease. American Journal of Preventive Medicine, 24(2), 136–142 (Feb).
Gertler, M., & White, P. D. (1954). Coronary heart disease in young adults: A multidisciplinary study. Cambridge, MA: Harvard University Press.
Thomas, C. B., & Cohen, B. H. (1955). The familial occurrence of hypertension and coronary artery disease, with observations concerning obesity and diabetes. Annals of Internal Medicine, 42, 90–127.
Rose, G. C. (1964). Familial patterns in ischaemic heart disease. British Journal of Preventive & Social Medicine, 18, 75–80.
Roberts, R., & McNally, E. M. (2007). Genetic basis for cardiovascular disease. In V. Fuster, R. W. Alexander, R. A. O'Rourke, R. Roberts, S. B. King III, I. S. Nash, et al. (Eds.), Hurst’s the heart (12 ed., pp. 1488–1590). New York: McGraw Hill.
Marian, A. J., Brugada, R., & Roberts, R. (2007). Cardiovascular diseases due to genetic abnormalities. In V. Fuster, R. W. Alexander, R. A. O'Rourke, R. Roberts, S. B. King III, I. S. Nash, et al. (Eds.), Hurst’s the heart (12th ed.). New York: McGraw Hill.
Roberts, R., & Gollob, M. H. (2006). Molecular cardiology and genetics in the 21st century—A primer. Current Problems in Cardiology, 31, 31(10), 637–701.
Wang, W. Y., Barratt, B., Clayton, D. G., & Todd, J. A. (2005). Genome-wide association studies: Theoretical and practical concerns. Nature Reviews. Genetics, 6, 109–118.
Hirshhorn, J. N., & Daly, M. J. (2005). Genome-wide association studies for common diseases and complex traits. Nature Reviews. Genetics, 6, 95–108.
Collins, F. S. (1999). Medical and societal consequences of the human genome project. The New England Journal of Medicine, 341(1), 28–37 (Jul 1).
Levy, S., Sutton, G., Ng, P. C., Feuk, L., Halpern, A. L., Walenz, B., et al. (2007). The diploid genome sequence of an individual human. PLoS Biology, 5(10), 1–32.
The International HapMap Consortium (2003). The International HapMap Project. Science, 426, 789–796.
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A. F. R., Cohen, J. C., Roberts, R., et al. (2007). A common allele on Chromosome 9 associated with coronary heart disease. Science, 316, 1488–1491.
Pare, G., Serre, D., Brisson, D., Anand, S., Montpetit, A., Tremblay, G., et al. (2007). Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. American Human Genetics, 80(4), 673–682.
Morgan, T. M., Krumholz, H. M., Lifton, R. P., & Spertus, J. A. (2007). Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA: The Journal of the American Medical Association, 297(14), 1551–1561 (Apr 11).
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., et al. (2007). A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 445(7130), 881–885 (Feb 22).
Graham, R. R., Kozyrev, S. V., Baechler, E. C., Reddy, M. V. P., Plenge, R. M., Bauer, J. W., et al. (2006). A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nature Genetics, 38(5), 550–555 (May).
Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J. P., Belaiche, J., et al. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature, 411(6837), 599–603 (May 31).
Amundadottir, L. T., Sulem, P., Gudmundsson, J., Helgason, A., Baker, A., Agnarsson, B. A., et al. (2006). A common variant associated with prostate cancer in European and African populations. Nature Genetics, 38(6), 652–658 (Jun).
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J. Y., Sackler, R. S., Haynes, C., et al. (2005). Complement factor H polymorphism in age-related macular degeneration. Science, 308(5720), 385–389 (Apr 15).
Loscalzo, J. (2007). Association studies in an era of too much information: Clinical analysis of new biomarker and genetic data. Circulation, 116(17), 1866–1870 (Oct 23).
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A. F. R., Cohen, J. C., Roberts, R., et al. (2007). A common allele on Chromosome 9 associated with coronary heart disease. Science, 316, 1488–1491.
Helgadottir, A., et al. (2007). A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science, 316(5830), 1491–1493.
Wellcome Trust Case Consortium (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 440(7145), 661–678 (Jun 7).
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., et al. (2007). Genomewide association analysis of coronary artery disease. The New England Journal of Medicine, 357(5), 443–53 (Jul 18).